Nucleic Acid Therapeutics CDMO Market - Global Forecast 2025-2032

The nucleic acid therapeutics CDMO market is evolving rapidly as advanced therapies drive demand for specialized development and manufacturing partnerships. In an environment shaped by technological change, regulatory complexity, and shifting global supply chains, senior executives must make informed decisions to align with growth and innovation opportunities.

Market Snapshot: Growth Trajectory and Strategic Shifts

According to recent analysis, the nucleic acid therapeutics CDMO market expanded from USD 10.77 billion in 2024 to USD 12.00 billion in 2025 and is on course to reach USD 26.14 billion by 2032, reflecting a robust CAGR of 11.71%.

Scope & Segmentation of the Nucleic Acid Therapeutics CDMO Market

This report provides a comprehensive segmentation to reflect critical dimensions within the industry:

• Therapeutics Type: DNA therapeutics, RNA therapeutics
• Service Type: Analytical testing & quality control, manufacturing, packaging & distribution, process development & optimization
• Therapeutic Applications: Genetic disorders, infectious diseases, neurological disorders, oncology, rare disorders
• End User: Academic & research institutes, biotechnology firms, pharmaceutical companies
• Regional Coverage: Americas (North America: United States, Canada, Mexico; Latin America: Brazil, Argentina, Chile, Colombia, Peru), Europe, Middle East & Africa (Europe: United Kingdom, Germany, France, Russia, Italy, Spain, Netherlands, Sweden, Poland, Switzerland; Middle East: United Arab Emirates, Saudi Arabia, Qatar, Turkey, Israel; Africa: South Africa, Nigeria, Egypt, Kenya), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Malaysia, Singapore, Taiwan)
• Technology Adoption: Synthetic gene synthesis, lipid nanoparticle delivery, microfluidic encapsulation, continuous bioprocessing, modular facility design, data analytics, and machine learning integration
• Key Companies Analyzed: AGC Biologics Inc., Agilent Technologies, Inc., Ajinomoto Bio-Pharma Services, Almac Group Ltd., Biomay AG, BioSpring GmbH, Catalent, Inc., Charles River Laboratories International, Inc., CordenPharma International GmbH, Creative Biogene, Danaher Corporation, Eurofins Scientific SE, Evonik Industries AG, GenScript Biotech Corporation, Lonza Group Ltd., Polypeptide Group AG, Recipharm AB, Rentschler Biopharma SE, Samsung Biologics, The Scripps Research Institute, Touchlight Group, Univercells Group, WuXi AppTec Co., Ltd.

Key Takeaways: Strategic Insights for Decision-Makers

• Specialized CDMOS are accelerating the commercialization of DNA and RNA therapies by offering tailored process development, analytical testing, and production solutions.
• Integrated digital ecosystems, including advanced analytics and machine learning, are strengthening real-time process control and predictive maintenance.
• Collaborative partnerships between biopharma innovators, equipment suppliers, and CDMOs are mitigating risks in supply continuity, regulatory compliance, and tech transfer.
• Platform standardization is advancing in tandem with custom offerings, allowing for streamlined workflows and adaptability to novel molecule classes.
• Operational excellence initiatives, such as digital twins and lean programs, are optimizing manufacturing yields and improving resource utilization.
• Sustainability is emerging as a competitive differentiator, with leaders adopting green chemistry and energy-efficient operations in line with stakeholder expectations.

Tariff Impact: Navigating Regulatory and Supply Chain Complexity

• Adjustments to United States tariff schedules on raw materials and specialty reagents have triggered a reassessment of global sourcing and production strategies.
• Industry participants are investing in domestic manufacturing, adopting dual-sourcing models, and expanding regional warehousing to minimize delays and input cost volatility.
• Strategic agreements and co-located manufacturing solutions are enabling flexibility and resilience in response to tariff-driven pressures.

Methodology & Data Sources

The research is anchored in a rigorous, multi-phase process combining secondary research from publications and patent databases with primary interviews of sector executives and technical specialists. Analytical approaches include SWOT analysis, value chain mapping, and scenario modeling, ensuring findings are validated and actionable.

Why This Report Matters

• Enables leadership teams to benchmark internal capabilities against key industry standards in technology adoption, service portfolios, and operational best practices.
• Equips procurement and strategic planning executives with the insights needed to navigate evolving regulatory, supply chain, and technological challenges.
• Supports investment prioritization by mapping opportunities across critical market segments, applications, and geographies.

Conclusion

This report provides a strategic framework for navigating the rapidly changing nucleic acid therapeutics CDMO market. By leveraging the insights presented, senior decision-makers can align growth initiatives with regulatory, technological, and operational demands for long-term advantage.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.